期刊文献+

叶酸在4例肾衰伴贫血患儿中的用药指征分析 被引量:1

The medication analysis of folic acid in four cases of children with renal failure and anemia
下载PDF
导出
摘要 目的通过叶酸在肾衰伴贫血患儿中的用药指征分析,不仅体现了临床药师在治疗过程中的作用,同时指导了患者合理用药。方法临床药师对4例肾衰伴贫血患儿服用叶酸的治疗过程进行监护,通过检测患儿叶酸水平,对叶酸在此类患儿中的用药指征进行把握。结果肾衰患儿不建议常规补充叶酸,由于过高的叶酸可能使肾衰患儿发生心功能异常,建议结合患儿叶酸水平及亚甲基四氢叶酸还原酶(MTHFR)代谢性,针对性服用叶酸降低肾衰患儿高同型半胱氨酸血症(HHcy)。结论临床药师在临床治疗的过程中,对叶酸在肾衰伴贫血患儿中的使用指征进行分析,指导了患者合理用药。 Objective To analyze the use of folic acid in the children with renal failure and anemia,which indicated the role of the clinical pharmacist in the therapeutic process and provided the reasonable medication guidelines.Methods 4 children with renal failure and anemia treated with folic acid were monitoring,and the medication of folic acid administration in children was controlled by determining the level of folic acid.Results Children with renal failure didn't recommend giving routine folic acid supplement,which due to the highly abnormal cardiac function caused by folic acid.It was recommended that we should take into account the folate levels and methylene tetrahydrofolate reductase(MTHFR) metabolism to administrate folic acid pertinently in order to lower the high hyperhomocysteinemia(HHcy) level in the children with renal failure.Conclusion Clinical pharmacists were involved in the adjustment of treatment program,meanwhile,the use of folic acid in children with renal failure and anemia was analyzed to reduce the occurance of short and long-term adverse reactions indicating the their professional value.
出处 《药学研究》 CAS 2018年第1期57-59,共3页 Journal of Pharmaceutical Research
基金 国家自然科学基金(No.81501579) 江苏省药学会基金科研项目(No.201507)
关键词 叶酸 肾衰 贫血 用药指征 临床药师 Folic acid Renal failure Anemia Medication Clinical pharmacist
  • 相关文献

参考文献4

二级参考文献31

  • 1Levin A,Thompson CR,Ethier J,et al.Left ventricular mass index increase in early renal disease:impact of decline in hemoglobin[J].Am J Kidney Dis,1999,34:125-134.
  • 2Mittal SK,Ahem L,Flaster E,et al.Self-assessed physical and mental function of haemodialysis patiens[J].Nephrol Dial Transplant,2001,16:1387-1394.
  • 3Moreno F,Sanz-Guajardo D,L6pez-Gómez JM,et al.Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients[J].J Am Soc Nephrol,2000,11:335-342.
  • 4Tsagalis G.Renal anemia:a nephrologist's view.Hippokratia[J].2011,15(Suppl 1):39-43.
  • 5McMurray JJV,Parfrey PS.KDIGO Clinical Practice Guideline Working Group.KDIGO Clinical practice guideline for anemia in chronic kidney disease[J].Kidney Int Suppl,2012,2:288-316.
  • 6National Kidney Foundation.Ⅳ.NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease:update 2000[J].Am J Kidney Dis,2001,37(1 Suppl 1):S182-S238.
  • 7中华医学会肾脏病学分会.重组人促红细胞生成素在肾性贫血中合理应用的专家共识[M].2010修订版.
  • 8Lee YK,Kim SG,Seo JW,et al.A comparison between once-weekly and twice-or thrice-weekly subcutaneous injection of epoetin alfa:results from a randomized controlled multicentre study[J].Nephrol Dial Transplant,2008,23:3240-3246.
  • 9Provenzano R,Garcia-Mayol L,Suchinda P,et al.Once-weekly epoetin alfa for treating the anemia of chronic kidney disease[J].Clin Nephrol,2004,61:392-405.
  • 10Tsubakihara Y,Nishi S,Akiba T,et al.2008 Japanese Society for Dialysis Therapy:guidelines for renal anemia in chronic kidney disease[J].Ther Apher Dial,2010,14:240-275.

共引文献193

同被引文献7

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部